nach oben

Erschienen in:

01.03.2015 | Maternal-Fetal Medicine

The association of lectin-like oxidized LDL receptor 1 (LOX-1) K167N and 3′UTR188CT polymorphisms with maternal plasma soluble LOX-1 levels and preeclampsia risk in Turkish population

verfasst von: Abdullah Tuten, Birsen Aydemir, Mahmut Oncul, Ali Riza Kiziler, Abdullah Serdar Acıkgoz, Gulcan Guntas Korkmaz, Volkan Sozer, Hafize Uzun

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the main effect of polymorphisms in genes involved in endothelial pathophysiological mechanisms, LOX-1 K167N and 3′UTR188CT single nucleotide polymorphisms (SNPs) in relation to preeclampsia (PE) risk and possible interactions between the gene polymorphisms and plasma oxLDL and soluble LOX-1 (sLOX-1) levels on PE in Turkish population.

Methods

LOX-1 K167N and 3′UTR188CT polymorphisms were studied in 113 pregnant women with preeclampsia and 96 healthy pregnant women by the PCR–RFLP techniques. sLOX-1 and oxLDL levels were determined by enzyme-linked immunosorbent assay (ELISA) in all study subjects.

Results

Patients having LOX-1 3′UTR188CT (OR 3.55, 95 % CI 1.89–6.67, P = 0.001) or 3′UTR188CC (OR 3.04, 95 % CI 1.25–7.38, P = 0.012) genotype had a significantly higher risk of PE than those with 3′UTR188TT genotype. Also, patients having K167N KK (OR 2.73, 95 % CI 1.33–5.61, P = 0.005) genotype had a significantly higher risk of PE than those with K167N NN genotype. LOX-1 3′UTR188TT and LOX-1 K167N NN genotype carriers were associated with significantly increased serum sLOX-1 level (P = 0.001). We further investigated the potential combined effect of these polymorphic variants on risk of PE development. According to the combined genotype analysis of LOX-1 3′UTR188TT and K167N NN polymorphisms, sLOX-1 and oxLDL levels also showed significant differences between PE patients and controls with or without combined TT/NN genotype carriers.

Conclusions

Our findings indicate that higher plasma sLOX-1 and oxLDL concentrations, and the LOX-1 3′UTR188C>T and LOX-1 K167N gene polymorphisms were significantly associated with risk of developing preeclampsia. Plasma sLOX-1 may be a potential therapeutic target in the treatment of preeclampsia.

Lima VJ, Andrade CR, Ruschi GE, Sass N (2011) Serum lipid levels in pregnancies complicated by preeclampsia. Sao Paulo Med J 129:73–76PubMed

Koga K, Izumi G, Mor G, Fujii T, Osuga Y (2014) Toll-like receptors at the maternal–fetal interface in normal pregnancy and pregnancy complications. Am J Reprod Immunol. doi:10.1111/aji.12258

Yin G, Zhu X, Guo C, Yang Y, Han T, Chen L, Yin W, Gao P, Zhang H, Geng J, Wang J, Liang L (2013) Differential expression of estradiol and estrogen receptor α in severe preeclamptic pregnancies compared with normal pregnancies. Mol Med Rep. 7(3):981–985PubMed

Cobellis L, De Falco M, Mastrogiacomo A, Giraldi D, Dattilo D, Scaffa C, Colacurci N, De Luca A (2007) Modulation of apelin and APJ receptor in normal and preeclampsia-complicated placentas. Histol Histopathol 22:1–8PubMed

Sahay AS, Patil VV, Sundrani DP, Joshi AA, Wagh GN, Gupte SA, Joshi SR (2014) A longitudinal study of circulating angiogenic and antiangiogenic factors and AT1-AA levels in preeclampsia. Hypertens Res. doi:10.1038/hr.2014.71 PubMed

Inoue N, Fujita Y, Sawamura T (2006) Progress in the research on LOX-1 and its clinical relevance. Nihon Yakurigaku Zasshi 127:103–108PubMedCrossRef

Al-Banna N, Lehmann C (2013) Oxidized LDL and LOX-1 in experimental sepsis. Mediators Inflamm 2013:761789PubMedCentralPubMedCrossRef

Fujita Y, Kakino A, Nishimichi N, Yamaguchi S, Sato Y, Machida S, Cominacini L, Delneste Y, Matsuda H, Sawamura T (2009) Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin Chem 55(2):285–294PubMedCrossRef

Hou XW, Son J, Wang Y, Ru YX, Lian Q, Majiti W, Amazouzi A, Zhou YL, Wang PX, Han ZC (2006) Granulocyte colony-stimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycin-induced cardiomyopathy in rats. Cardiovasc Drugs Ther 20(2):85–91PubMedCrossRef

10.

Morawietz H, Rueckschloss U, Niemann B, Duerrschmidt N, Galle J, Hakim K, Zerkowski HR, Sawamura T, Holtz J (1999) Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 100(9):899–902PubMedCrossRef

11.

Predazzi IM, Norata GD, Vecchione L, Garlaschelli K, Amati F, Grigore L, Cutuli L, Pirillo A, Tramontana S, Romeo F, Novelli G, Catapano AL (2012) Association between OLR1 K167N SNP and intima media thickness of the common carotid artery in the general population. PLoS ONE 7(2):e31086. doi:10.1371/journal.pone.0031086 PubMedCentralPubMedCrossRef

12.

Kume N, Kita T (2001) Roles of lectin-like oxidized LDL receptor-1 and its soluble forms in atherogenesis. Curr Opin Lipidol 12:419–423PubMedCrossRef

13.

Morawietz H (2010) LOX-1 receptor as a novel target in endothelial dysfunction and atherosclerosis. Dtsch Med Wochenschr 135:308–312PubMedCrossRef

14.

Yamanaka S, Zhang XY, Miura K, Kim S, Iwao H (1998) The human gene encoding the lectin-type oxidized LDL receptor (OLR1) is a novel member of the natural killer gene complex with a unique expression profile. Genomics 54:191–199PubMedCrossRef

15.

ACOG practice bulletin (2002) Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 99:159–167CrossRef

16.

Trabetti E, Biscuola M, Cavallari U, Malerba G, Girelli D, Olivieri O, Martinelli N, Corrocher R, Pignatti PF (2006) On the association of the oxidised LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction or coronary artery disease. Eur J Hum Genet 14:127–130PubMedCrossRef

17.

Chen Q, Reis SE, Kammerer C, Craig WY, LaPierre SE, Zimmer EL, McNamara DM, Pauly DF, Sharaf B, Holubkov R, Bairey Merz CN, Sopko G, Bontempo F, Kamboh MI (2003) Genetic variation in lectin-like oxidized low-density lipoprotein receptor 1 (LOX1) gene and the risk of coronary artery disease. Circulation 107:3146–3151PubMedCrossRef

18.

Tatsuguchi M, Furutani M, Hinagata J, Tanaka T, Furutani Y, Imamura S, Kawana M, Masaki T, Kasanuki H, Sawamura T, Matsuoka R (2003) Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction. Biochem Biophys Res Commun. 303(1):247–250PubMedCrossRef

19.

Hou XW, Yang RQ, Zhong YG, Gao W, Sun SP, Wang NF (2011) G501C polymorphism of the oxidized LDL receptor gene is associated with albuminuria in Chinese essential hypertension patients. Genet Mol Res 10(4)

20.

Kurnaz O, Aydogan HY, Isbir CS, Tekeli A, Isbir T (2009) Is LOX-1 K167N polymorphism protective for coronary artery disease? In Vivo 23(6):969–973PubMed

21.

Xu X, Hou X, Liang Y, Li F, Pang L, Huang G, Huang J, Shi M, Sun X, Wang Y (2014) The gene polymorphism of LOX1 predicts the incidence of LVH in patients with essential hypertension. Cell Physiol Biochem 33(1):88–96PubMedCrossRef

22.

Ohki I, Ishigaki T, Oyama T, Matsunaga S, Xie Q, Ohnishi-Kameyama M, Murata T, Tsuchiya D, Machida S, Morikawa K, Tate S (2005) Crystal structure of human lectin-like, oxidized low-density lipoprotein receptor 1 ligand binding domain and its ligand recognition mode to OxLDL. Structure 13(6):905–917PubMedCrossRef

23.

Chen M, Inoue K, Narumiya S, Masaki T, Sawamura T (2001) Requirements of basic amino acid residues within the lectin-like domain of LOX-1 for the binding of oxidized low-density lipoprotein. FEBS Lett 499(3):215–219PubMedCrossRef

24.

Kurnaz O, Akadam-Teker AB, Yilmaz-Aydoğan H, Tekeli A, Isbir T (2012) The LOX-1 3′UTR188CT polymorphism and coronary artery disease in Turkish patients. Mol Biol Rep 39(4):4351–4358PubMedCrossRef

25.

Mango R, Clementi F, Borgiani P, Forleo GB, Federici M, Contino G, Giardina E, Garza L, Fahdi IE, Lauro R, Mehta JL, Novelli G, Romeo F (2003) Association of single nucleotide polymorphisms in the oxidised LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction. J Med Genet 40:933–936PubMedCentralPubMedCrossRef

26.

Sentinelli F, Filippi E, Fallarino M, Romeo S, Fanelli M, Buzzetti R, Berni A, Baroni MG (2006) The 3′-UTR C>T polymorphism of the oxidized LDL-receptor 1 (OLR1) gene does not associate with coronary artery disease in Italian CAD patients or with the severity of coronary disease. Nutr Metab Cardiovasc Dis 16:345–352PubMedCrossRef

27.

Brinkley TE, Kume N, Mitsuoka H, Brown MD, Phares DA, Ferrell RE, Kita T, Hagberg JM (2008) Variation in the human lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) gene is associated with plasma soluble LOX-1 levels. Exp Physiol 93(9):1085–1090PubMedCentralPubMedCrossRef

28.

Mango R, Biocca S, del Vecchio F, Clementi F, Sangiuolo F, Amati F, Filareto A, Grelli S, Spitalieri P, Filesi I, Favalli C, Lauro R, Mehta JL, Romeo F, Novelli G (2005) In vivo and in vitro studies support that a new splicing isoform of OLR1 gene is protective against acute myocardial infarction. Circ Res 97(2):152–158PubMedCrossRef

29.

Palmieri VO, Coppola B, Grattagliano I, Casieri V, Cardinale G, Portincasa P, Palasciano G, Di Serio F (2013) Oxidized LDL receptor 1 gene polymorphism in patients with metabolic syndrome. Eur J Clin Invest 43:41–48PubMedCrossRef

30.

Lee H, Park H, Kim YJ, Kim HJ, Ahn YM, Park B, Park JH, Lee BE (2005) Expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in human preeclamptic placenta: possible implications in the process of trophoblast apoptosis. Placenta 26:226–233PubMedCrossRef

31.

Mehta JL, Li DY (1998) Identification and autoregulation of receptor for OX-LDL in cultured human coronary artery endothelial cells. Biochem Biophys Res Commun 248:511–514PubMedCrossRef

32.

Mitra S, Goyal T, Mehta JL (2011) Oxidized LDL, LOX-1 and atherosclerosis. Cardiovasc Drugs Ther 25:419–429PubMedCrossRef

33.

Uzun H, Benian A, Madazli R, Topçuoğlu MA, Aydin S, Albayrak M (2005) Circulating oxidized low-density lipoprotein and paraoxonase activity in preeclampsia. Gynecol Obstet Invest 60:195–200PubMedCrossRef

34.

English FA, McCarthy FP, McSweeney CL, Quon AL, Morton JS, Sawamura T, Davidge ST, Kenny LC (2013) Inhibition of lectin-like oxidized low-density lipoprotein-1 receptor protects against plasma-mediated vascular dysfunction associated with pre-eclampsia. Am J Hypertens 26:279–286PubMedCrossRef

35.

Chigusa Y, Tatsumi K, Kondoh E, Fujita K, Nishimura F, Mogami H, Konishi I (2012) Decreased lectin-like oxidized LDL receptor 1 (LOX-1) and low Nrf2 activation in placenta are involved in preeclampsia. J Clin Endocrinol Metab 97:E1862–E1870PubMedCrossRef

36.

Murase T, Kume N, Kataoka H, Minami M, Sawamura T, Masaki T, Kita T (2000) Identification of soluble forms of lectin-like oxidized LDL receptor-1. Arterioscler Thromb Vasc Biol 20:715–720PubMedCrossRef

37.

Ohmori R, Momiyama Y, Nagano M, Taniguchi H, Egashira T, Yonemura A, Nakamura H, Kondo K, Ohsuzu F (2004) An oxidized low-density lipoprotein receptor gene variant is inversely associated with the severity of coronary artery disease. Clin Cardiol 27(11):641–644PubMedCrossRef

38.

Hayashida K, Kume N, Murase T, Minami M, Nakagawa D, Inada T, Tanaka M, Ueda A, Kominami G, Kambara H, Kimura T, Kita T (2005) Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation 112:812–818PubMedCrossRef

Titel: The association of lectin-like oxidized LDL receptor 1 (LOX-1) K167N and 3′UTR188CT polymorphisms with maternal plasma soluble LOX-1 levels and preeclampsia risk in Turkish population
verfasst von: Abdullah Tuten
Birsen Aydemir
Mahmut Oncul
Ali Riza Kiziler
Abdullah Serdar Acıkgoz
Gulcan Guntas Korkmaz
Volkan Sozer
Hafize Uzun
Publikationsdatum: 01.03.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 3/2015
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-014-3457-4

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

Centering Pregnancy: practical tips for your practice

Treatment cost evaluation of extrauterine gravidity: a literature review of medical and surgical treatment costs

Impact of sperm cell source on the results of intracytoplasmic sperm injection

The relationship between the VEGF/sVEGFR-1 ratio and threatened abortion